Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000227331 | SCV000283167 | likely benign | Hereditary breast ovarian cancer syndrome | 2023-12-22 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV000583967 | SCV000688703 | uncertain significance | Hereditary cancer-predisposing syndrome | 2019-05-30 | criteria provided, single submitter | clinical testing | |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000985463 | SCV001133675 | uncertain significance | not provided | 2018-10-23 | criteria provided, single submitter | clinical testing | |
University of Washington Department of Laboratory Medicine, |
RCV000583967 | SCV003849968 | likely benign | Hereditary cancer-predisposing syndrome | 2023-03-23 | criteria provided, single submitter | curation | Missense variant in a coldspot region where missense variants are very unlikely to be pathogenic (PMID:31911673). |
Ambry Genetics | RCV000583967 | SCV004052660 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-09-12 | criteria provided, single submitter | clinical testing | The p.L428V variant (also known as c.1282C>G), located in coding exon 9 of the BRCA2 gene, results from a C to G substitution at nucleotide position 1282. The leucine at codon 428 is replaced by valine, an amino acid with highly similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |